Clinical trials: Type 2 Diabetic
Diabetes Mellitus, Type 2
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.
- Trial name
- NCT00819091
- Testing
- BI 1356
- Where
- 45 sites in United States, Argentina and 5 more
- Volunteers
- 245 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes…
- Trial name
- DUAL™ II Japan (NCT02911948)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 38 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetes Mellitus, Type 2
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- NCT01301456
- Testing
- PF-04856883
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs
This trial is conducted in Africa. The aim of this clinical trial is to investigate the effect of 50 weeks of treatment with different intensified insulin administrations (all in combination with a fixed dose of metformin) on…
- Trial name
- NCT01068652
- Testing
- insulin detemir, insulin aspart, biphasic insulin aspart 30
- Where
- 19 sites in Algeria, Egypt and 3 more
- Volunteers
- 403 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels.
- Trial name
- CGM_IRB-3 (NCT03290768)
- Testing
- Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Savvysherpa, Inc.
Type 2 Diabetes Mellitus
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics
The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.
- Trial name
- NCT00486291
- Testing
- VI-0521
- Where
- 9 sites in United States
- Volunteers
- 210 people
- Sponsor
- VIVUS LLC
Diabetes Mellitus, Diabetic Kidney Disease
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
SGLT2 inhibitors such as ertugliflozin improve blood pressure and kidney outcomes in people living with diabetes through incompletely understood mechanisms, however, not all patients treated with SGLT2 inhibition have improved…
- Conditions
- Diabetes Mellitus, Diabetic Kidney Disease, Hypertension
- Trial name
- DESIGN (NCT05727579)
- Testing
- Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetic Retinopathy
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various…
- Trial name
- NCT00542178
- Testing
- Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,472 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Type II Diabetes
Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers
The primary objective of this study is to compare the rate of healing as well as percent of wounds healed in Type II diabetic patients with chronic foot ulcerations receiving sitagliptin versus placebo.
- Trial name
- NCT02015910
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Georgetown University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Efficacy of Lubiprostone in Combination With Standard PEG Preparation
A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population.
- Trial name
- NCT00689026
- Testing
- Lubiprostone, Polyethylene glycol with electrolytes
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Augusta University
Pre-diabetic, Diabetic Type II Mellitus
Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs
The incidence of type 2 diabetes mellitus (T2DM) is increasing rapidly. The combination of T2DM and smoking is particularly lethal, as smokers with T2DM are significantly more likely to develop a number of health related…
- Trial name
- OMSCinDEP (NCT01980017)
- Testing
- Ottawa Model for Smoking Cessation
- Where
- Canada
- Volunteers
- 313 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Diabetes Mellitus, Type 2
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control.
- Trial name
- NCT00789035
- Testing
- BI 10773, metformin
- Where
- 74 sites in Argentina, Croatia and 11 more
- Volunteers
- 408 people
- Sponsor
- Boehringer Ingelheim
Diabetes
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how…
- Trial name
- NCT00737633
- Testing
- VI-0521
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- VIVUS LLC
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
- Trial name
- NCT00736099
- Testing
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Where
- 232 sites in United States, Argentina and 30 more
- Volunteers
- 2,122 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.
- Trial name
- NCT00707993
- Testing
- Alogliptin, Glipizide
- Where
- 80 sites in United States, Hungary and 9 more
- Volunteers
- 441 people
- Sponsor
- Takeda
Diabetic Nephropathy
Study Of Diabetic Nephropathy With Atrasentan
The study objective was to evaluate the effect of atrasentan compared with placebo on time to doubling of serum creatinine (DBSC) or the onset of end-stage renal disease (ESRD) in participants with type 2 diabetes and nephropathy…
- Trial name
- SONAR (NCT01858532)
- Testing
- Atrasentan
- Volunteers
- 5,107 people
- Sponsor
- AbbVie
Type 2 Diabetes
DIabetic Retinopathy Candesartan Trials
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252694)
- Testing
- candesartan
- Volunteers
- 4,717 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus, Type 2
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
The purpose of this study is to assess the safety and tolerability of MSDC-0602 and to evaluate the reduction in fasting plasma glucose in patients with Type 2 diabetes.
- Trial name
- NCT01280695
- Testing
- MSDC-0602 100 mg, MSDC-0602 250 mg, Pioglitazone
- Where
- 14 sites in United States
- Volunteers
- 129 people
- Sponsor
- Metabolic Solutions Development Company